The PPARγ Agonist Rosiglitazone Is Antifibrotic for Scleroderma Lung Fibroblasts: Mechanisms of Action and Differential Racial Effects
We present novel data demonstrating that the expression of PPARγ is reduced in lung fibroblasts from black SSc-ILD patients as compared to white patients. Activating PPARγ with the agonist rosiglitazone increased the expression of MMP-1 and inhibited collagen type I in lung fibroblasts isolated from...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Pulmonary Medicine |
| Online Access: | http://dx.doi.org/10.1155/2012/545172 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832556180107427840 |
|---|---|
| author | Galina S. Bogatkevich Kristin B. Highland Tanjina Akter Richard M. Silver |
| author_facet | Galina S. Bogatkevich Kristin B. Highland Tanjina Akter Richard M. Silver |
| author_sort | Galina S. Bogatkevich |
| collection | DOAJ |
| description | We present novel data demonstrating that the expression of PPARγ is reduced in lung fibroblasts from black SSc-ILD patients as compared to white patients. Activating PPARγ with the agonist rosiglitazone increased the expression of MMP-1 and inhibited collagen type I in lung fibroblasts isolated from white, but not black, SSc-ILD patients. Blocking the c-Met receptor abolishes rosiglitazone's effects on collagen and MMP-1 in lung fibroblasts isolated from white SSc-ILD patients, while augmenting the expression of the c-Met receptor in fibroblasts from black SSc-ILD patients replicates the effects of rosiglitazone seen in whites. We conclude that PPARγ agonists warrant consideration as potential antifibrotic drugs in patients with SSc-ILD. Differential therapeutic effects might be anticipated especially relative to racial differences and the functional expression of the c-Met receptor. |
| format | Article |
| id | doaj-art-400e4df50848430bab014c5bf8606db9 |
| institution | Kabale University |
| issn | 2090-1836 2090-1844 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Pulmonary Medicine |
| spelling | doaj-art-400e4df50848430bab014c5bf8606db92025-02-03T05:46:06ZengWileyPulmonary Medicine2090-18362090-18442012-01-01201210.1155/2012/545172545172The PPARγ Agonist Rosiglitazone Is Antifibrotic for Scleroderma Lung Fibroblasts: Mechanisms of Action and Differential Racial EffectsGalina S. Bogatkevich0Kristin B. Highland1Tanjina Akter2Richard M. Silver3Division of Rheumatology and Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 912, Charleston, SC 29425-6370, USADivision of Rheumatology and Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 912, Charleston, SC 29425-6370, USADivision of Rheumatology and Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 912, Charleston, SC 29425-6370, USADivision of Rheumatology and Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 912, Charleston, SC 29425-6370, USAWe present novel data demonstrating that the expression of PPARγ is reduced in lung fibroblasts from black SSc-ILD patients as compared to white patients. Activating PPARγ with the agonist rosiglitazone increased the expression of MMP-1 and inhibited collagen type I in lung fibroblasts isolated from white, but not black, SSc-ILD patients. Blocking the c-Met receptor abolishes rosiglitazone's effects on collagen and MMP-1 in lung fibroblasts isolated from white SSc-ILD patients, while augmenting the expression of the c-Met receptor in fibroblasts from black SSc-ILD patients replicates the effects of rosiglitazone seen in whites. We conclude that PPARγ agonists warrant consideration as potential antifibrotic drugs in patients with SSc-ILD. Differential therapeutic effects might be anticipated especially relative to racial differences and the functional expression of the c-Met receptor.http://dx.doi.org/10.1155/2012/545172 |
| spellingShingle | Galina S. Bogatkevich Kristin B. Highland Tanjina Akter Richard M. Silver The PPARγ Agonist Rosiglitazone Is Antifibrotic for Scleroderma Lung Fibroblasts: Mechanisms of Action and Differential Racial Effects Pulmonary Medicine |
| title | The PPARγ Agonist Rosiglitazone Is Antifibrotic for Scleroderma Lung Fibroblasts: Mechanisms of Action and Differential Racial Effects |
| title_full | The PPARγ Agonist Rosiglitazone Is Antifibrotic for Scleroderma Lung Fibroblasts: Mechanisms of Action and Differential Racial Effects |
| title_fullStr | The PPARγ Agonist Rosiglitazone Is Antifibrotic for Scleroderma Lung Fibroblasts: Mechanisms of Action and Differential Racial Effects |
| title_full_unstemmed | The PPARγ Agonist Rosiglitazone Is Antifibrotic for Scleroderma Lung Fibroblasts: Mechanisms of Action and Differential Racial Effects |
| title_short | The PPARγ Agonist Rosiglitazone Is Antifibrotic for Scleroderma Lung Fibroblasts: Mechanisms of Action and Differential Racial Effects |
| title_sort | pparγ agonist rosiglitazone is antifibrotic for scleroderma lung fibroblasts mechanisms of action and differential racial effects |
| url | http://dx.doi.org/10.1155/2012/545172 |
| work_keys_str_mv | AT galinasbogatkevich theppargagonistrosiglitazoneisantifibroticforsclerodermalungfibroblastsmechanismsofactionanddifferentialracialeffects AT kristinbhighland theppargagonistrosiglitazoneisantifibroticforsclerodermalungfibroblastsmechanismsofactionanddifferentialracialeffects AT tanjinaakter theppargagonistrosiglitazoneisantifibroticforsclerodermalungfibroblastsmechanismsofactionanddifferentialracialeffects AT richardmsilver theppargagonistrosiglitazoneisantifibroticforsclerodermalungfibroblastsmechanismsofactionanddifferentialracialeffects AT galinasbogatkevich ppargagonistrosiglitazoneisantifibroticforsclerodermalungfibroblastsmechanismsofactionanddifferentialracialeffects AT kristinbhighland ppargagonistrosiglitazoneisantifibroticforsclerodermalungfibroblastsmechanismsofactionanddifferentialracialeffects AT tanjinaakter ppargagonistrosiglitazoneisantifibroticforsclerodermalungfibroblastsmechanismsofactionanddifferentialracialeffects AT richardmsilver ppargagonistrosiglitazoneisantifibroticforsclerodermalungfibroblastsmechanismsofactionanddifferentialracialeffects |